IPSEN - Buy-back Programme - Art 5 of MAR - Week 23 - 2024

Yahoo FinanceJun 11 12:00 ET

FDA Fast-Tracks Ipsen And Genfit's New Liver Disease Treatment, Iqirvo

Ipsen SA (OTC:IPSEF) (OTC:IPSEY) announced Monday that the U.S. Food and Drug Administration (FDA) had granted accelerated approval for Iqirvo (elafibranor) 80 mg tablets to treat primary biliary chol

BenzingaJun 11 09:18 ET

Ipsen Gains Accelerated Approval for Elafibranor for Rare Liver Disease

Seeking AlphaJun 10 17:33 ET

GENFIT Says Iqirvo Is First-ever Drug Developed In-house By Company To Achieve FDA Approval; Expects To Receive Milestone Payments From Ipsen

GENFIT is eligible to receive a €48.7 million milestone payment from Ipsen upon the first commercial sale of Iqirvo in the U.S., as well as tiered double-digit royalties of up to 20%.Ipsen's Iqirvo (e

BenzingaJun 10 17:26 ET

Ipsen and Marengo Therapeutics Announce Second Strategic Partnership

Seeking AlphaJun 7 08:53 ET

Ipsen Presents Long-term Elafibranor Efficacy and Itch-related Quality of Life Data in Patients With Primary Biliary Cholangitis

Ipsen (Euronext: IPN; ADR: IPSEY) today announced new late-breaking data at the European Association for the Study of the Liver (EASL) Congress demonstrating the enduring efficacy of elafibranor in managing disease progression after 78 weeks of treatment.

GlobeNewswireJun 5 02:00 ET